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Abstract
Background: Nuclear factor E2 related factor-2 (Nrf2) is an oxidative stress inducible transcription factor being
essential in regulating cell homeostasis. Thus, acute induction of Nrf2 in epithelial cells exposed to inflammation
confers protection from oxidative cell damage and mutagenesis supporting an anti-tumorigenic role for Nrf2.
However, pancreatic ductal adenocarcinoma (PDAC) is characterized by persistent Nrf2 activity conferring therapy
resistance which points to a pro-tumorigenic role of Nrf2. A similar dichotomous role in tumorigenesis is described
for the Transforming Growth Factor-beta 1 (TGF-β1). The present study therefore aimed at elucidating whether the
switch of Nrf2 function towards a tumor promoting one relates to the modulation of TGF-β1 induced cell responses
and whether this might occur early in PDAC development.
Methods: In situ analysis comprised immunohistochemical stainings of activated (phosphorylated) Nrf2 and Ki67 in
pancreatic tissues containing normal ducts and pancreatic intraepithelial neoplasia (PanINs). In vitro, Nrf2 levels in
benign (H6c7-pBp), premalignant (H6c7-kras) and malignant (Colo357) pancreatic ductal epithelial cells were
modulated by Nrf2 specific siRNA or Nrf2 overexpression. Then, the effect of Nrf2 alone and in combination with
TGF-β1 on cell growth and survival was investigated by cell counting, Ki67 staining and apoptosis assays. The
underlying cell signaling was investigated by western blotting. Statistical analysis was performed by Shapiro-Wilk
test for normal distribution. Parametric data were analyzed by one-way ANOVA, while non-parametric data were
analyzed by Kruskal-Wallis one-way ANOVA on ranks.
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Results: Significantly elevated expression of activated Nrf2 and Ki67 could be detected in PanINs but not in
normal pancreatic ductal epithelium. While the effect of Nrf2 on basal cell growth of H6c7-pBp, H6c7-kras and
Colo357 cells was minor, it clearly attenuated the growth inhibiting effects of TGF-β1 in all cell lines. This enhanced
Nrf2-mediated cell survival was predominantly based on an enhanced proliferative activity. Accordingly, expression
of p21 expression along with expression of phospho-p38 and phospho-Smad3 was diminished whereas
Erk-phosphorylation was enhanced under these conditions.
Conclusions: Overall, our data demonstrate that Nrf2 being elevated in early precursor lesions counteracts the
growth inhibiting function of TGF-β1 already in benign and premalignant pancreatic ductal epithelial cells. This
could represent one fundamental mechanism underlying the functional switch of both- TGF-β1 and Nrf2 – which
may manifest already in early stages of PDAC development.
Keywords: Chronic pancreatitis, Pancreatic cancer precursor lesion, Oxidative stress, TGF-β1, Proliferation,
Pancreatic cancer
Background
Pancreatic ductal adenocarcinoma (PDAC) is still a lead-
ing cause of cancer related deaths in western countries
with a poor 5-year survival rate of 6 % [1]. This can be
mainly explained by the late diagnosis when the disease
has been already progressed to an advanced stage and a
profound therapy resistance. Accordingly, much effort is
given to a better understanding of the early steps of
PDAC development in order to identify targets that
can be used for screening tests, early diagnosis and/or
chemoprevention.
Precursor lesions of PDAC predominantly originate
from ductal cells with pancreatic intraepithelial neoplasia
(PanIN) being the most frequent and best characterized
precursor lesions of PDAC [2]. One of the earliest gen-
etic alterations which is present in 99 % of even early
PanINs (PanIN1) is the mutation of the oncogene kras
[3] being an essential driver of PDAC development [4].
Besides the genetic alterations, one hallmark of PDAC is
its pronounced stromal microenvironment comprising
stellate cells, myofibroblasts and diverse immune cells
together with extracellular matrix [5–8] which start to
accumulate in earliest PanINs [9].
Besides cancer cells themselves, myofibroblasts and
immune cells such as macrophages are a main source of
Transforming Growth Factor-beta1 (TGF-β1) [5, 10]. Al-
though TGF-β1 is able to potently inhibit the growth of
cells including transformed cells and thereby acts as
tumor suppressor, it also represents an important key
driver in tumor development, e.g. of PDAC, by promot-
ing invasion, metastasis and chemoresistance of tumor
cells as well as immunosuppression and angiogenesis
[10, 11]. TGF-β1 can exert its pleiotropic functions via
the Smad-dependent (canonical) signaling pathway or
via signaling through various Smad-independent path-
ways e.g. the Mitogen-activated protein kinases (MAPK)
p38 and Erk1/2, the latter ones contributing to TGF-β1
responsiveness even in the presence of mutations in the
Smad4/DPC4 gene [12]. Thus, the function of TGF-β1
is a double-edged sword and the switch from tumor sup-
pressor to a tumor promoter seems to be context
dependent, albeit the exact underlying mechanisms are
still poorly understood [12, 13].
A similar dual role in tumorigenesis has been de-
scribed for the antioxidative transcription factor Nuclear
factor E2 related factor-2 (Nrf2) [14–16]. In response to
metabolic, xenobiotic or oxidative stress (e.g. in the
course of inflammation), Nrf2 becomes activated leading
to transcription of a variety of genes contributing to res-
toration of redox and cell homeostasis, e.g. antioxidant
enzymes NAD(P)H dehydrogenase [quinone] 1 (NQO1),
Hemoxygenase (HO)-1, anti-apoptotic proteins such as
Bcl-2 or metabolic enzymes [16]. However, constitutive
high expression and activity of Nrf2 have been described
for several tumors including PDAC [17] contributing to
chemo-/radioresistance [18–21], enhanced cell motility
[22], metabolic reprogramming [23], maintenance of
self-renewal of cancer stem cells [24] as well as en-
hanced proliferation [17, 25]. In an endogenous PDAC
mouse model it was shown that oncogenic kras signaling
leads to tumor cell proliferation and tumorigenesis via
elevation of Nrf2 activity [25]. The fact that TGF-β1 and
Nrf2 both become upregulated upon persistent inflam-
mation suggests that these two factors may virtually im-
pact on their signaling pathways paving the way for their
switch from tumor suppressor to tumor promoter. Ac-
cordingly, it has been shown that Nrf2 can inhibit the
profibrotic action of TGF-β1 by preventing Smad3 acti-
vation [26, 27]. Thus, the present study intends to inves-
tigate whether Nrf2 contributes to the pro-tumorigenic
switch of TGF-β1 in PDAC by antagonizing the TGF-β1
mediated growth inhibiting effect on pancreatic ductal
epithelial cells thereby undergoing a functional switch it-
self. In order to verify whether this switch might occur
at early stages of PDAC development, particular em-
phasis was given to the in situ analyses of activated Nrf2
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and Ki67 in early PanINs. In vitro, the interplay of Nrf2
and TGF-β1 on cell growth was investigated on three
pancreatic ductal epithelial cell lines resembling different
stages of PDAC development, namely benign H6c7-pBp,
premalignant H6c7-kras and malignant Colo357 cells.
Overall, our study provides ample evidence that the
functional switch of Nrf2 occurs early in PDAC develop-
ment based on its ability to counteract the growth inhi-
biting function of TGF-β1.
Methods
Cell lines and cell culture
As model for benign pancreatic ductal epithelium, the
human pancreatic ductal epithelial cell line H6c7-pBp
and as model for premalignant pancreatic ductal epithe-
lium harboring a krasG12V mutation, the cell line H6c7-
kras [28] were used, both well-established cell models
and kindly provided by M.S. Tsao (Ontario Cancer Insti-
tute, Toronto, Canada). Both cell lines were cultured in
H6c7-medium (50 % RPMI 1640 medium (Biochrom,
Berlin, Germany) and 50 % KSF-medium (Gibco Life
Technologies, Darmstadt, Germany) supplemented with
5 % fetal calf serum, 0.5 % L-glutamine (both Biochrom),
50 μg/mL bovine pituitary extract, 5 ng/mL epidermal
growth factor (both Gibco Life Technologies) + 0.5 μg/
mL puromycin (Invitrogen, Darmstadt, Germany). The
human pancreatic ductal epithelial cell line Colo357 was
kindly provided by H. Kalthoff, Institute of Experimental
Cancer Research, Kiel, Germany) and kept in Colo357-
medium which is composed of RPMI-1640 medium
supplemented with 1 % L-glutamine, 10 % FCS and 1 %
sodium pyruvate. Colo357 cells used in this study harbor
a wild type Smad4/DPC4 genotype [29] and are genetic-
ally distinct from those Colo357 cells having a homozy-
gous deletion of the Smad4 gene [30].
Knock-down of Nrf2
To suppress endogenous Nrf2 expression, 1 × 105 cells/
well of H6c7-pBp, H6c7-kras and Colo357 cells were
seeded in 12-well plates containing 1 mL medium/well.
For transfection, medium was removed and 1 mL fresh
medium was added. Then, 6 μL/well HiperFect reagent
(Qiagen, Hilden, Germany) and 75 ng/well of either
negative control siRNA or specific Nrf2 siRNA (no.
SI03246614, both from Qiagen) were mixed with 100 μL
FCS-free medium and added to the cells. Specificity of
the siRNA was confirmed previously [18]. After 24 h,
cells were either left untreated or treated with 10 ng/mL
TGF-β1 (BioLegend, Fell, Germany) for 48 h.
Overexpression of Nrf2
To overexpress Nrf2 in H6c7-pBp and H6c7-kras cells,
either cell line was seeded into 6 well plates (2 x 105
cells/well). After 24 h, medium was removed and
replaced by 1,6 mL fresh medium. Then, 100 μL/well
EC-puffer, 8 μL/μg plasmid Enhancer and 20 μL/μg plas-
mid Effectene (all from Qiagen) together with 0,3 μg/
well of either pcDNA3.1 control vector (pcDNA3.1; Invi-
trogen) or pcDNA3.1 encoding Nrf2-HA were mixed
and added to the cells. After 16 h, medium was replaced
by 2 mL/well of fresh H6c7- or Colo357 medium and
cells were either left untreated or treated with 10 ng/mL
TGF-β1 for 48 h.
Western blotting
Preparation of whole cell lysates and nuclear extracts as
well as electrophoresis and western blotting have been
described elsewhere [31, 32]. The following antibodies
were used according to the manufacturer’s instructions:
rabbit anti-HSP90α/β (clone H-114), mouse anti-lamin-
A/C (clone 346), goat anti-Smad2/3 (clone E-20) (all
from Santa Cruz, Heidelberg, Germany), rabbit anti-
Erk1/Erk2, rabbit anti-phospho Erk1/Erk2 (T204/Y209),
rabbit anti-p38, mouse anti-phospho p38 (T180/Y182,
clone D3F9), rabbit anti-phospho Smad3 (Ser423/425),
rabbit anti-PARP (all from Cell Signaling via New Eng-
land Biolabs, Frankfurt/a.M., Germany), mouse anti-p21
(clone 187) (BD Biosciences, Heidelberg, Germany),
monoclonal rabbit anti-Nrf2 (clone EP1808Y, Abcam,
Berlin, Germany), mouse anti-tubulin (clone B-5-1-2)
and rabbit anti-HA (both from Sigma-Aldrich, Tauf-
kirchen, Germany). Primary antibodies were incubated
overnight at 4 ° C and detected by anti-rabbit, anti-goat
or anti-mouse HRP-linked antibodies (Cell Signaling) at
room temperature for 1 h. After washing in TBST, blots
were developed with SuperSignal West Dura Extended
Duration Substrate (Perbio Sciences, Bonn, Germany).
Average band intensities were determined by densitom-
etry using ImageI 1.47v software (National Institute of
Health). Values of the proteins of interest were divided
by the values of the corresponding loading control
(Hsp90). Additionally, values of phosphorylated proteins
were divided by the values of the corresponding total
protein (data are presented in Additional file 1: Figure
S2A + C).
Determination of vital cell number
After detachment with trypsin-EDTA (PAA, Pasching,
Austria), cells were stained with trypan blue (Sigma-Al-
drich, Munich, Germany) and counted using a Neubauer
counting chamber. For quantification of vital cells, blue
stained cells were excluded from counting.
Ki67 staining
For Ki67 staining, cells were seeded on cover slips
(ThermoScientific, Schwerte, Germany) before transfec-
tion and stimulation procedures. Then, medium was
removed, cells were washed with PBS and fixed with ice-
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cold acetone + 0.3 % H2O2 for 10 min. After washing in
PBS, cells were blocked in 4 % BSA/PBS for 20 min.
Cells were incubated with 2 μg/mL mouse IgG1 anti-
Ki67 antibody (BD Biosciences, Heidelberg, Germany)
diluted in 1 % BSA/PBS at RT for 45 min. Cells were
washed with PBS and incubated with EnVision-HRP
anti-mouse (Dako, Hamburg, Germany) for 30 min,
washed with PBS and incubated with AEC Substrate
(Dako) for 2-10 min. After final washing in PBS, cells
were stained in Mayer’s Haemalaun (AppliChem, Darm-
stadt, Germany) for 2 min. After washing in water for
10 min, cover slips were fixed with Kaiser’s glycerine gel-
atine (Waldeck, Münster, Germany). Initial isotype
control stainings were performed with a mouse IgG1
antibody (R&D Systems, Wiesbaden, Germany) under
identical conditions revealing no staining. Evaluation
was done using an EvosxL Core microscope (AMG,
Bothell, USA). Quantification of Ki67 positive cells was
performed at a 200-fold magnification by choosing 5
representative visual fields in each counting positively
stained as well as negative cells along a diagonal line
using Microsoft Powerpoint 2007 in order to calculate
the percentage of Ki67 positive cells. If less than ten cells
touched the line, all captured cells of the visual field
were counted.
Measurement of apoptosis
Determination of caspase-3/7 activity was performed in
transfected and stimulated H6c7-kras and Colo357 cells
using a Caspase-Glo® 3/7 assay (Promega, Mannheim,
Germany), according to the manufacturer’s instructions
and as described [32, 33]. All samples were measured in
duplicates.
Immunohistochemistry
Paraffin-embedded and formalin-fixed postmortem pan-
creatic tissues of 22 individuals that had died of non-
pancreatic diseases were used for immunohistochemical
analysis. The research was approved by the ethics com-
mittee of the Semmelweis University, Budapest, Hungary
(140-1/1996). The need for an informed consent was
waived by the ethics committee of the Semmelweis
University, Budapest, Hungary according to national reg-
ulations. Only tissues that have been extensively charac-
terized were used [34, 35]. Consecutive 3 μm thick
tissue sections were deparaffinized and rehydrated as
previously described [8]. Staining for Ki67 (clone SP6,
Fisher/Thermo Scientific) was performed at the Institute
of Pathology using an automated routine procedure. For
staining of p-Nrf2, antigen retrieval was performed with
1:10 diluted citrate buffer at pH 6.0 for 20 min. After
washing, sections were incubated either with a monoclo-
nal rabbit anti-phospho(Ser40)-Nrf2 (1 μg/ml; clone
EP18094, Abcam) diluted in 1 % BSA and 0.3 % Triton-
X-100/PBS at 4 °C overnight. After washing, sections
were incubated with EnVision-HRP anti-rabbit (Dako)
for 45 min at room temperature. Substrate reaction was
performed with AEC Substrate (Dako) for 10 min. After
washing, cells were stained in Mayer’s Haemalaun
(Merck, Darmstadt, Germany) for 2 min. After washing
in water for 10 min, sections were covered with Kaiser’s
glycerine gelatine (Roth, Karlsruhe, Germany). Usage of
control antibodies revealed no or only weak background
staining.
Evaluation
Stained tissue sections were evaluated twice in a blinded
manner by scoring the extent of distribution (given as
%-positivity of the whole section). In case of two dis-
crepant results, sections were evaluated by a second in-
vestigator. If possible, 10 normal ducts and PanINs were
analysed in each pancreatic tissue. Each parameter was
evaluated using a 5-score system (1 = negative, 2 = <10 %
positive, 3 = 11–50 % positive, 4 = 51–90 % positive, 5 =
more than 90 % positive). To enable performance of
statistical analysis, the created groups of tissue samples
per score were then dichotomized by the median score
and refitted into two groups of < median (low expres-
sion) and ≥median (high expression). Evaluation of the
sections was carried out using an Axioplan 2.0 micro-
scope (Zeiss, Jena, Germany). Pictures were taken using
a Keyence BZ9000 microscope (Keyence, Neu-Isenburg,
Germany).
Statistical analysis
Relationships between data from immunohistochemical
stainings of pancreatic tissues were categorized and
compared between groups by Fisher’s exact test using
SPSS 17.0 (IBM, Ehningen, Germany). Statistical analysis
of in vitro data was performed using SigmaPlot Software
12.5 (Systat Software GmbH, Erkrath, Germany). The
Shapiro-Wilk test was used to test for normal distribu-
tion. Parametric data were analyzed by one-way RM
ANOVA, while non-parametric data were analyzed by
Kruskal-Wallis one-way ANOVA on ranks test. P-values
< 0.05 were regarded as statistically significant and are
indicated with an asterisk (*).
Results
Expression of activated Nrf2 is elevated in early PanINs
correlating with an increased proliferative activity
To elucidate whether early PanIN lesions already exhibit
greater Nrf2 activity and whether this correlates with an
increased proliferative activity, phospho-Nrf2 (p-Nrf2),
representing activated Nrf2, as well as Ki67 were immu-
nohistochemically detected and scored in normal ducts
and PanINs of pancreatic tissues from 22 individuals
which had died from non-pancreatic diseases (Tables 1
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and 2). While the majority of normal ducts showed no
or only weak p-Nrf2 expression (16/21 with low expres-
sion, Fig. 1a), significantly elevated p-Nrf2 expression (=
high expression) was detected in PanINs of 17/20 tissues
(Fig. 1b). Ki67 expression was elevated in 45 % (10/22
with high expression) of normal ducts, but in all ana-
lyzed PanINs (Fig. 1, Tables 1 and 2). Moreover, this ele-
vated proliferative activity of PanINs was significantly
associated with increased p-Nrf2 expression (Table 3)
supporting the view that Nrf2 activity accounts for
higher proliferation of pancreatic ductal epithelial cells
already in early PanINs.
Nrf2 antagonizes the growth inhibiting effect of TGF-β1
on benign, premalignant and malignant pancreatic ductal
epithelial cells
Animal based studies revealed that oncogene activation
can lead to enhanced Nrf2 mediated gene transcription
accounting for increased proliferation and tumorigenesis
[25]. To investigate the impact of Nrf2 on cell growth of
human pancreatic ductal epithelial cells, pancreatic ductal
epithelial cell lines were used resembling different stages
of PDAC development: 1) benign H6c7-pBp cells lacking
any of the known mutations driving pancreatic tumori-
genesis [28], 2) premalignant H6c7-kras cells harboring a
krasG12V mutation [28] and 3) malignant Colo357 cells
[36]. Since TGF-β1 is elevated at early stages of PDAC de-
velopment, too, the investigations focused on the interplay
between Nrf2 and TGF-β1. As demonstrated by immun-
cytochemical staining (Fig. 2a,b) and western blotting
(Fig. 2c), basal nuclear Nrf2 expression could be detected
in all three pancreatic duct cell lines with the lowest ex-
pression in benign H6c7-pBp cells and the highest nuclear
Nrf2 expression in malignant Colo357 cells (Fig. 2a-c). In
line with our recent findings [37], treatment with 10 ng/ml
Table 1 Initial scoring of p-Nrf2 and Ki67 expression in normal pancreatic ducts and PanINs
Normal ducts PanINs
Marker Score 1 Score 2 Score 3 Score 4 Score 5 Score 1 Score 2 Score 3 Score 4 Score 5 Median score
p-Nrf2 16 5 0 0 0 3 13 4 0 0 2
Ki67 12 10 0 0 0 0 15 4 0 0 2
Table 2 Interrelationship of p-Nrf2 and Ki67 expression in normal
pancreatic ducts and PanINs, initial scores were dichotomized by
the median score and refitted into 2 groups of low and high
expression
Normal ducts (n = 22) PanINs (n = 20) p-value
Marker Low High Low High
p-Nrf2 16/21 5/21 3/20 17/20 0.002
Ki67 12/22 10/22 0/19 19/19 0.001
In two cases, no PanINs were detectable
Fig. 1 Expression of activated Nrf2 is elevated in PanINs correlating with
an increased proliferative activity. Representative immunhistochemical
stainings of activated (phosphorylated) Nrf2 (p-Nrf2) and Ki67 in (a)
normal pancreatic ducts and (b) PanINs of two individuals. Magnification
x400 and x800 (frames)
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TGF-β1 for 48 h led to an induction of Nrf2 expression in
all three cell lines (Fig. 2a-c).
Next it was analyzed how Nrf2 impacts on cell growth of
pancreatic ductal epithelial cells. For this purpose, H6c7-
pBp and H6c7-kras cells exhibiting low and moderate basal
Nrf2 expression, respectively (see Fig. 2), were transfected
with Nrf2-HA and being either left untreated or treated
with 10 ng/ml TGF-β1. After 48 h, vital cell numbers were
determined. Compared to control transfected cells, in which
TGF-β1 treatment significantly reduced the number of vital
H6c7-pBp and H6c7-kras cells by 30 and 46.6 %, respect-
ively, overexpression of Nrf2 clearly diminished the growth
inhibiting effect of TGF-β1 treatment on both cell lines (10
and 31 %, respectively, compared to untreated cells) (Fig. 3a).
The transfection efficiency was confirmed by detecting the
HA-tag by western blotting using an HA-specific antibody
for specific detection of recombinant Nrf2 (Fig. 3a bottom
panel) and realtime PCR based determination of elevated
expression of the Nrf2 target gene NQO1 (data not shown).
In order to verify the interference of Nrf2 with the growth
inhibitory effect of TGF-β1 in all three pancreatic ductal
epithelial cell lines, Nrf2 siRNA knockdown experiments
were conducted. As demonstrated in Fig. 3b, knockdown of
Nrf2 clearly enhanced the growth inhibiting effect of TGF-
β1 in H6c7-pBp, H6c7-kras and Colo357 cells. Transfection
efficiency was confirmed by detecting endogenous total-
Nrf2 by western blotting (Fig. 3b, bottom panel) and real-
time PCR based determination of reduced expression of the
Nrf2 target gene NQO1 (data not shown). Overall, these
data indicate that Nrf2 potently antagonizes the growth
inhibiting function of TGF-β1 in human pancreatic ductal
epithelial cells.
Nrf2 increases proliferation of benign, premalignant and
malignant pancreatic ductal epithelial cells
To elucidate how Nrf2 antagonizes the growth inhibiting
effect of TGF-β1, proliferation of H6c7-pBp, H6c7-kras
and Colo357 cells was analyzed in dependence on Nrf2
and TGF-β1. As demonstrated in Fig. 4a-c, TGF-β1
treatment drastically reduced the overall cell number
as well as the number of Ki67 positive H6c7-pBp,
H6c7-kras and Colo357 cells that had been trans-
fected with the empty vector. In contrast, overexpres-
sion of Nrf2 clearly attenuated this effect of TGF-β1
and increased the cell density along with the number
of Ki67 positive H6c7-pBp and H6c7-kras cells
(Fig. 4a). In line with these findings, knockdown of
Nrf2 in H6c7-pBp, H6c7-kras and Colo357 cells in-
creased the antiproliferative effect of TGF-β1 as indi-
cated by a further reduced cell number and less Ki67
expressing cells (Fig. 4b, c). Similar results were ob-
tained by MTT assay (data not shown) supporting the
view that Nrf2 antagonizes the growth inhibiting ef-
fect of TGF-β1 by counteracting its antiproliferative
activity in pancreatic ductal epithelial cells.
Nrf2 only slightly impact on basal and TGF-β1 induced
apoptosis in pancreatic ductal epithelial cells
Since the growth inhibiting effect of TGF-β1 may also
involve an increase of apoptosis, we next investigated
the impact of Nrf2 on basal and TGF-β1 mediated apop-
tosis in the three pancreatic ductal epithelial cell lines.
As shown in Fig. 5a, the basal apoptotic rate as deter-
mined by caspase-3/7 activity correlated well with the
basal Nrf2 expression in the three pancreatic ductal epi-
thelial cell lines. Hence, H6c7-pBp cells with the lowest
basal Nrf2 activity (see also Fig. 2) exhibited the highest
basal caspase-3/7 activity while Colo357 cells - showing
the highest Nrf2 expression - were characterized by the
lowest caspase-3/7 activity. Accordingly, when overex-
pressing Nrf2 in H6c7-pBp cells the basal (Fig. 5b) as
well as the TGF-β1 mediated (Fig. 5c) apoptotic rate was
clearly reduced, whereas Nrf2 overexpression in H6c7-
kras cells only slightly affected basal and TGF-β1
dependent apoptosis. In line with the overexpression ex-
periments, suppression of Nrf2 by siRNA transfection
mainly increased the basal caspase-3/7 activity of H6c7-
pBp cells but only slightly in H6c7-kras and Colo357
cells (Fig. 5d). Moreover, the TGF-β1 mediated apoptosis
was marginally affected by Nrf2 suppression in all three
cell lines (Fig. 5e). In order to validate these moderate
Nrf2 mediated effects on apoptosis induction observed
in H6c7-pBp and H6c7-kras cells by caspase-3/7 activity
assay, PARP cleavage was analysed in the same cells by
western blotting. Even though slight differences in the
full length form of PARP were observed, cleaved PARP
could be detected in neither sample (Additional file 2:
Figure S1). These data indicate that the interference of
Nrf2 with the growth suppression by TGF-β1 mainly re-
lies on the reversal of its antiproliferative activity (see
above) and to lesser extent on the protection from TGF-
β1 dependent apoptosis.
Table 3 Association between p-Nrf2 and Ki67 expression in
normal pancreatic ducts and PanINs, expressed as p-values from
chi-square test
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Nrf2 modulates MAPK and Smad signaling in benign,
premalignant and malignant pancreatic ductal epithelial
cells
Next it was investigated how Nrf2 antagonizes TGF-β1
mediated growth inhibition. For this purpose the impact
of Nrf2 on relevant signaling pathways, such as MAPK
and Smad signaling as well as the expression of the
cyclin-dependent kinase inhibitor 1 (p21) was analysed.
As shown in Fig. 6a, overexpression of Nrf2 which was
demonstrated by detecting the HA-tag of recombinant
Nrf2 (see Fig. 3a) reduced basal as well as TGF-β1 medi-
ated phosphorylation of p38. Likewise, Smad3 phosphor-
ylation was also reduced by Nrf2 overexpression, albeit
at lesser extent (Fig. 6a, Additional file 1: Figure S2A +
B). Conversely, Nrf2 overexpression increased phosphor-
ylation of the proliferation associated MAPK Erk in
H6c7-pBp and H6c7-kras cells (Fig. 6a, Additional file 1:
Figure S2A+B). Moreover, expression levels of p21 were
reduced by Nrf2 overexpression in H6c7-kras cells in the
absence and presence of TGF-β1 while in H6c7-pBp cells
a marked effect of Nrf2 overexpression was observed
solely in the presence of TGF-β1 (Fig. 6a, Additional file 1:
Figure S2A + B).
To confirm the effects of Nrf2 on these growth control-
ling mediators, Nrf2 knock-down experiments were con-
ducted with all three pancreatic ductal epithelial cell lines.
siRNA mediated suppression of Nrf2 in H6c7-pBp, H6c7-
kras and Colo357 cells, as demonstrated by detection of
reduced levels of endogenous total-Nrf2 (see Fig. 3b), en-
hanced basal as well as TGF-β1 induced phosphorylation
of p38 and Smad3 along with an elevated expression of
p21. By contrast, TGF-β1 mediated phosphorylation of
Erk was clearly reduced in the absence of Nrf2 (Fig. 6b,
Additional file 1: Figure S2C +D). Overall, these data sup-
port the view that Nrf2 antagonizes TGF-β1 mediated
growth suppression by attenuating the growth inhibiting
(p38 and Smad3) signaling pathways and concomitantly
enhancing growth promoting Erk-signaling.
Discussion
The dual role of TGF-β1 in tumorigenesis of epithelial tu-
mors is well established. Under physiological conditions,
Fig. 2 Different Nrf2 expression in benign, premalignant and
malignant pancreatic ductal epithelial cells. H6c7-pBp, H6c7-kras and
Colo357 cells were either left untreated or were treated with 10 ng/
ml TGF-β1 for 48 h. Representative immunocytochemical stainings
of (a) total (t)-Nrf2 and (b) phospho (p)-Nrf2. Magnification x 280
(magnification of images in frames x 540). c Representative western
blots showing t-Nrf2 and p-Nrf2 expression in nuclear extracts of
H6c7-pBp, H6c7-kras and Colo357 cells either left untreated or
treated with 10 ng/ml TGF-β1 for 48 h. Lamin-A, tubulin and Hsp90
were detected as loading control for nuclear, cytosolic and total cell
extracts, respectively
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TGF-β1 is an essential cell growth inhibitor and thereby
prevents epithelial hyperproliferation and the onset of epi-
thelial tumors. However, TGF-β1 becomes a potent tumor
promoter through its capacity to initiate EMT, to enhance
cell migration and invasion and to favour chemoresistance
[12, 13], applying also to PDAC [38–40]. Moreover, ex-
perimental evidence indicate that this functional switch
might occur already at early stages in tumorigenesis when
epithelial cells still do not harbour any of the driver muta-
tions or at least only single mutations, such as in the k-ras
oncogene [37, 39]. This functional switch of TGF-β1 lead-
ing to reprogramming of its activated signaling pathways
seems to be context dependent, albeit the underlying
mechanisms are still not fully understood. One mechan-
ism explaining the TGF-β1 paradox might be the differen-
tial activation of MAPK such as Erk in benign and
malignant epithelial cells [12]. Many tumors exhibit con-
stitutive high Erk activation due to a mutation in the ras
oncogene, leading to sustained TGF-β1 synthesis and sig-
naling. In line with this, Gotzmann et al. showed that
Fig. 3 Nrf2 antagonizes the growth inhibiting effect of TGF-β1 on pancreatic ductal epithelial cells. a H6c7-pBp and H6c7-kras cells that were
transfected with a control vector (pcDNA3.1) or Nrf2-HA and left untreated or were treated with 10 ng/ml TGF-β1 for 48 h. Determination of vital
cell numbers by trypan blue exclusion and cell counting. Verification of Nrf2 overexpression was performed by western blotting using an HA-specific
antibody and Hsp90 as loading control. b H6c7-pBp, H6c7-kras and Colo357 cells were transfected either with control siRNA or Nrf2 siRNA and left
untreated or were treated with 10 ng/ml TGF-β1 for 48 h. Determination of vital cell numbers by trypan blue exclusion and cell counting. Verification
of Nrf2 knockdown was performed by western blotting using a t-Nrf2 antibody and Hsp90 as loading control. Data of vital cell numbers are presented
as Box-Plots of 4-6 independent experiments. * = p < 0.05
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cooperation of TGF-β1 signaling and oncogenic expres-
sion of Ha-ras promotes a mesenchymal and invasive
phenotype in hepatocytes [41]. Furthermore, sustained
MAPK activation can also result from prolonged exposure
to a plethora of inflammatory mediators (e.g. IL-6, TNF-α,
TGF-β1) upon chronic inflammation [42, 43]. Thus, our
study extends this view by demonstrating that sustained
high expression and activity of the antioxidative transcrip-
tion factor Nrf2 essentially contributes to deregulation of
TGF-β1 signaling by reducing Smad3 and p38 activation
and augmenting Erk activation resulting in reduced p21
expression and enhanced proliferation of pancreatic ductal
epithelial cells. One can speculate that an elevated Nrf2
activity leads to changes in the assembly of TGF-β I (Alk1
and Alk5) and TGF-β II receptors, thereby favouring an
altered recruitment of downstream mediators that can
initiate Smad independent/non-canonical pathways like
Ras-ERKs. Thus, further studies have to unravel in
more detail how Nrf2 suppresses TGF-β1 mediated
Smad3 and p38 activation and concomitantly enhance
Erk signaling. Interestingly, we could observe these ef-
fects likewise in benign, premalignant and malignant
pancreatic ductal epithelial cells suggesting that high
Nrf2 activity can promote this functional switch of
TGF-β1 already early in tumorigenesis. Favoring this
hypothesis, we could detect enhanced expression of ac-
tivated (phosphorylated) Nrf2 in nuclei of early PanINs
being significantly associated with a higher proliferative
activity exemplified by elevated Ki67 expression. More-
over, these data are in line with findings from an en-
dogenous PDAC mouse model showing that oncogenic
kras activation is one key mechanism leading to sus-
tained Nrf2 expression and activity driving pancreatic
tumorigenesis [25]. Hence, pancreata of Nrf2 deficient
mice exhibited fewer PanINs with lower proliferative
activity than the wildtype mice whereas no differences
in the extent of apoptotic cells could be observed [25].
Thus, activation of the ras-raf-Erk pathway [25, 44]
Fig. 4 Nrf2 increases proliferation of benign, premalignant and
malignant pancreatic ductal epithelial cells. Representative Ki67
stainings of (a) H6c7-pBp and H6c7-kras cells that were transfected
with a control vector (pcDNA3.1) or Nrf2-HA and left untreated or
were treated with 10 ng/ml TGF-β1 for 48 h, and (b) H6c7-pBp,
H6c7-kras and (c) Colo357 cells that were transfected either with
control siRNA or Nrf2 siRNA and left untreated or were treated with
10 ng/ml TGF-β1 for 48 h. Magnification x280 (magnification of
images in frames x540). Quantification of Ki67 positive cells was
performed at a 200-fold magnification by choosing 5 representative
visual fields, in each counting positively stained as well as negative
cells along a diagonal line using Microsoft Powerpoint 2007 in order
to calculate the percentage of Ki67 positive cells. If less than ten cells
touched the line, all captured cells of the visual field were counted.
Data are expressed as mean ± SD of counted cells from 5 visual
fields. * = p < 0.05
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Fig. 5 (See legend on next page.)
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represents an important mechanism leading to en-
hanced Nrf2 expression and activity in tumor cells,
applying also to pancreatic ductal epithelial cells. Ac-
cordingly, we could demonstrate higher basal Nrf2 ex-
pression and activity in H6c7-kras and Colo357 cells
compared to benign H6c7-pBp cells. Important to note,
constitutive Nrf2 activation is caused to a lesser extent
by genetic alterations affecting either the Nrf2 inhibitor
Keap1 or Nrf2 itself (accounting for 10–15 % in gall-
bladder and ovarian cancer or in lung cancer up to
30 % of enhanced Nrf2 activation) as well as epigenetic
mechanisms accounting for enhanced Nrf2 activity in
20–30 % of tumors [45, 46]. Accordingly, we previously
showed that PDAC cells with different Nrf2 activity
exhibit similar Keap1 expression levels [18] supporting the
view that sustained Nrf2 activation in PDAC cells is not
caused by epigenetic or genetic alterations of Keap1 and
rather than other factors. Besides the above mentioned
oncogene induced Nrf2 activation, the exposure of epithe-
lial cells to persistent metabolic and/or oxidative stress,
e.g. caused by the presence of ROS releasing macrophages
and neutrophils during the course of a chronic inflamma-
tion [47] is a major cause for constitutive elevated Nrf2 ac-
tivity. Macrophages are not only abundant in chronic
pancreatitis and PDAC [8] but start to accumulate around
early PanINs. Hence, the growing inflammatory micro-
environment together with oncogenic kras activation in
ductal epithelial cells, which is present in almost all early
PanINs [3], may promote upregulation of both Nrf2 and
TGF-β1 activity already at this early stage of PDAC devel-
opment. Supporting this view, we previously demon-
strated that predominantly proinflammatory macrophages
releasing ROS at high levels lead to nuclear accumulation
of Nrf2 in colonic epithelial cells conferring apoptosis
resistance towards TRAIL or the chemotherapeutic drug
irinotecan [47]. This Nrf2 mediated apoptosis resistance
relied on Nrf2 enhanced proteasomal gene expression
[47], a mechanism that apparently also operates in PDAC
cells [18].
In contrast to the findings of Lister et al., in our stud-
ies the effect of Nrf2 per se on cell growth of pancreatic
ductal epithelial cells was minor [17] which might be ex-
plained by different cultivation periods after modulation
of Nrf2 expression. Nrf2 essentially impacts on cell sur-
vival of pancreatic ductal epithelial cells by antagonizing
the growth inhibitory effect of TGF-β1 by diminishing
TGF-β1 induced p21 expression and accelerating Erk
signaling resulting in increased proliferation. Besides a
pro-proliferative function, Nrf2 has been described to
confer profound protection from apoptosis by e.g. up-
regulation of anti-apoptotic proteins such as bcl-2 or
bcl-xL [19, 20] or proteasomal genes such as s5a/psmd4
or α5/psma5 [18]. Thus, elevated Nrf2 expression is one
pivotal mechanism underlying chemoresistance of many
tumors, e.g. PDAC [18–21]. Accordingly, in this study
the highest Nrf2 expression/activity could be correlated
with the lowest apoptosis rate in Colo357 cells and vice
versa. However, overexpression or knock down of Nrf2 in
pancreatic ductal epithelial cells only slightly modulated
TGF-β1 mediated apoptosis induction. Thus, Nrf2 appar-
ently enhances the growth of pancreatic ductal epithelial
cells predominantly by antagonizing the proliferation inhi-
biting effect of TGF-β1. Since this phenomenon could
be observed not only in malignant but also in premalig-
nant and benign epithelial cells, one can speculate that
the switch of Nrf2 from tumor suppressor to a tumor
promoter might occur quite early in tumorigenesis and
in particular in the concomitant presence of TGF-β1.
Conclusions
Overall this study provides a novel mechanism explain-
ing the functional switch of Nrf2 and TGF-β1, both fac-
tors that exert anti-tumorigenic functions and
contribute to cell/tissue homeostasis under physio-
logical and acute inflammatory conditions but which
likewise are able to promote tumor development.
Hence, concomitant and persistent elevation of both
factors leads to deregulation of the activated signaling
pathways thereby fostering survival and growth of
transformed cells as well as cell invasion [37]. Thus,
this might also explain why therapeutic strategies tar-
geting only either factor have been proven less effective.
Therefore, future studies have to investigate whether
concomitant targeting of Nrf2 and TGF-β1 will be
more efficient in the treatment of highly malignant tu-
mors such as PDAC.
(See figure on previous page.)
Fig. 5 Nrf2 hardly impact on basal and TGF-β1 induced apoptosis in pancreatic ductal epithelial cells. a, d, e H6c7-pBp, H6c7-kras and Colo357
cells were transfected either with control siRNA or Nrf2 siRNA or (b, c) H6c7-pBp and H6c7-kras cells were transfected with a control vector
(pcDNA3.1) or Nrf2-HA. Then, cells were either left untreated or were treated with 10 ng/ml TGF-β1 for 48 h. Caspase-3/7 activity was determined
and normalized to the cell number. a Basal caspase-3/7 activity of control siRNA, untreated H6c7-pBp, H6c7-kras and Colo357 cells, expressed as
n-fold caspase-3/7 activity of H6c7-pBp cells which were set as 1. b Caspase-3/7 activity in H6c7-pBp and H6c7-kras after overexpression of
Nrf2-HA or (d) siRNA mediated Nrf2 suppression, expressed as n-fold caspase-3/7 activity of the corresponding control transfected cell line which
was set as 1. c + e Caspase-3/7 activity in TGF-β1 treated H6c7-pBp and H6c7-kras after (c) overexpression of Nrf2-HA or (e) siRNA mediated Nrf2
suppression, expressed as n-fold caspase-3/7 activity of the corresponding control transfected, TGF-β1 treated cell line which was set as 1. Data
are presented as mean ± SD of 3-5 independent experiments. * = p < 0.05
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Additional files
Additional file 1: Figure S2. Nrf2 modulates MAPK and Smad
signaling in benign, premalignant and malignant pancreatic ductal
epithelial cells. A + B) H6c7-pBp and H6c7-kras cells were transfected
with a control vector (pcDNA3.1) or Nrf2-HA or (C + D) H6c7-pBp,
H6c7-kras and Colo357 cells were transfected either with control siRNA
or Nrf2 siRNA. Then, cells were either left untreated or were treated
with 10 ng/ml TGF-β1 for 48 h. A + C) Densitometric analysis of p-p38,
p-Smad3, p-Erk and p21 expression normalised to Hsp90 expression in
the indicated samples. Data are presented as mean ± SD of three
independent experiments. B + D) Representative western blots of 3-4
independent experiments showing expression of phosphorylated and
total p38 (p-/t-p38), phosphorylated Smad3 (p-Smad3 marked by arrow)
and total-Smad3 (t-Smad3 marked by arrow) and phosphorylated and
total Erk (p-/t-Erk). Hsp90 was detected as loading control. Numbers
above each band indicate average band intensities determined by
densitometry. Values of phosphorylated proteins were divided by the
values of the corresponding total protein. Nrf2 overexpression was
confirmed by detecting the HA-tag of recombinant Nrf2 (see Fig. 3a)
and siRNA mediated suppression of endogenous Nrf2 was confirmed
by detection of total-Nrf2 (t-Nrf2, see Fig. 3b). (PDF 273 kb)
Additional file 2: Figure S1. Nrf2 hardly impact on basal and TGF-β1
induced apoptosis in pancreatic ductal epithelial cells. H6c7-pBp and
H6c7-kras cells were transfected either with (A) a control vector
(pcDNA3.1) or Nrf2-HA or (B) control siRNA or Nrf2 siRNA. Then, cells were
either left untreated or were treated with 10 ng/ml TGF-β1 for 48 h. Cells
were detached and one part was used for determining caspase-3/7 activity.
The other part was used for cell counting and normalization of caspase-3/7
activity. Then, these cells were lysed in Laemmli buffer and analysed for
PARP (full length 116 kD form and cleaved 89 kD form) by western blotting.
Hsp90 was detected as loading control. One representative result is shown.
(PDF 159 kb)
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